Hepatology - Givlaari
Customize your policy alerts
Sign up for Cigna Policy IP0118 alerts
Get alerted when Policy IP0118 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and benefit coverage for Givlaari (givosiran) for patients with acute hepatic porphyria, subject to the applicable benefit plan, laws, and individual clinical circumstances.
The initial approval duration for acute hepatic porphyria was increased from 6 months to 1 year.
The biochemical diagnostic criterion was revised to require elevated urinary porphobilinogen rather than elevated urinary or plasma porphobilinogen.
The prerequisite acute attack criterion was revised to specify intravenous hemin administration at home.
The medical geneticist was removed from the list of acceptable prescribing or consulting specialists.
Reauthorization criteria were removed from the policy revision history.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.